This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-24 and is reviewed periodically as new material appears.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Certain other achievements of the democratic period having to do with the management of governmental and civic institutions necessary to the functioning of the reunited state and nation were too easily overlooked. Lurking on the sidelines was a disgusted army officer corps unwilling to subject itself to civilian control, but ready to follow the retired Piłsudski, who was highly popular with Poles and just as dissatisfied with the Polish system of government as his former colleagues in the military.
ISBN 0-921991-50-9. Spaeter, Helmuth (1990). Panzerkorps Grossdeutschland: A Pictorial History. Atglen, Pennsylvania: Schiffer Books. ISBN 0-88740-245-3. Ziemke, Earl F. (2002). Stalingrad to Berlin: The German Defeat in the East. Washington, D.C.: Center of Military History. ISBN 978-1-78039-287-5.
FIAU is then phosphorylated stepwise: thymidine kinase (TK) converts FIAU to FIAU-monophosphate (FIAU-MP), then thymidylate kinase (TMPK) forms FIAU-diphosphate (FIAU-DP) and finally nucleoside-diphosphate kinase (DPK) produces FIAU-triphosphate (FIAU-TP). FIAU-TP can be incorporated into viral or cellular DNA (figure 4). In addition, thymidylate synthase (TS) has the potential to de-iodinate FIAU to FAU and then subsequently methylate FAU to FMAU monophosphate. FMAU monophosphate can subsequently be converted into FMAU diphosphate by thymidine monophosphate kinase (TMPK). Finally, FMAU diphosphate can be converted into FMAU triphosphate by the enzyme diphosphate kinase (DPK) with the purpose of incorporation into the viral or cellular DNA. FIAU does not exist as only one compound inside the cell, its metabolites can also contribute and FAU can ultimately be incorporated as FMAU in whole cells.
A few incidents have occurred when radioactive material was disposed of improperly, shielding during transport was defective, or when it was simply abandoned or even stolen from a waste store. In the Soviet Union, waste stored in Lake Karachay was blown over the area during a dust storm after the lake had partly dried out. In Italy, several radioactive waste deposits let material flow into river water, thus contaminating water for domestic use. In France in the summer of 2008, numerous incidents happened: in one, at the Areva plant in Tricastin, it was reported that, during a draining operation, liquid containing untreated uranium overflowed out of a faulty tank and about 75 kg of the radioactive material seeped into the ground and, from there, into two rivers nearby; in another case, over 100 staff were contaminated with low doses of radiation. There are ongoing concerns around the deterioration of the nuclear waste site on the Enewetak Atoll of the Marshall Islands and a potential radioactive spill. Scavenging of abandoned radioactive material has been the cause of several other cases of radiation exposure, mostly in developing nations, which may have less regulation of dangerous substances (and sometimes less general education about radioactivity and its hazards) and a market for scavenged goods and scrap metal. The scavengers and those who buy the material are almost always unaware that the material is radioactive and it is selected for its aesthetics or scrap value.
Insulin glulisine is a rapid-acting modified form of insulin used to treat diabetes. It differs from human insulin by replacing the amino acid asparagine at position B3 with lysine and the lysine at position B29 with glutamic acid. When injected subcutaneously, it enters the bloodstream faster than regular human insulin (RHI). It was developed by Sanofi. The most common side effect is hypoglycemia (low blood glucose levels). Insulin glulisine was approved for medical use in the United States and the European Union in 2004. It is currently patented by Sanofi, and is therefore only produced by said company under the brand name Apidra.
Sources: en.wikipedia.org
Amino acid response is the mechanism triggered in mammalian cells by amino acid starvation. The amino acid response pathway is triggered by shortage of any essential amino acid, and results in an increase in activating transcription factor ATF4, which in turn affects many processes by sundry pathways to limit or increase the production of other proteins. Essential amino acids are crucial to maintain homeostasis within an organism. Diet plays an important role in the health of an organism, as evidence ranging from human epidemiological to model organism experimental data suggests that diet-dependent pathways impact a variety of adult stem cells.
== Computing == Opus (audio format), an audio coding format Opus (microkernel), an operating system kernel Opus-CBCS, a computer bulletin board system Directory Opus, a file manager program OPUS (software), digital repository software Claude Opus, a version of the Claude (language model)
==== Clash jumpers ==== In 2007, the AFL Commission laid down the requirement that all clubs must produce an alternative jumper for use in matches where jumpers are considered to clash. From 2007 to 2011, the Essendon clash guernsey was the same design as its home guernsey, but with a substantially wider sash such that the guernsey was predominantly red rather than predominantly black. This was changed after 2011 when the AFL deemed that the wider sash did not provide sufficient contrast. From 2012 to 2016, Essendon's clash guernsey was predominantly grey, with a red sash fimbriated in black; the grey field contained, in small print, the names of all Essendon premiership players. Before the 2016 season, Essendon's changed their clash guernsey to a predominantly red one, featuring a red sash outlined in black. Similar to the grey jumper, the names of Essendon premiership players were also printed outside the sash. The 2025 season saw Essendon unveil a new away/clash guernsey, which is red with a black sash, a reverse of the home guernsey.
It is on the World Health Organization's List of Essential Medicines for its obstetric uses. Lubiprostone is a PGE1 derivative used to treat chronic constipation. It is taken orally. Common side effects include diarrhea, vomiting, and abdominal pain.
He first called for only a pause in fighting, saying that he "doesn't know if a ceasefire is possible with an organization like Hamas", but later called for a humanitarian ceasefire and urged Biden to withhold military aid to Israel. Sanders accused Israel of mass starvation, ethnic cleansing, and extermination. Sanders initially said that allegations of genocide had to be adjudicated by the International Court of Justice, but in September 2025 he said: "The intent is clear. The conclusion is inescapable: Israel is committing genocide in Gaza." Addressing Westminster College in a September 2017 speech, Sanders laid out a foreign policy plan for greater international collaboration, adherence to US-led international agreements such as the Paris Agreement and the Iran nuclear deal framework and promoting human rights and democratic ideals. He emphasized the consequences associated with global economic inequality and climate change and urged reining in the use of US military power, saying it "must always be a last resort". He also criticized US support for "murderous regimes" during the Cold War, such as those in Iran, Chile and El Salvador and said that those actions continue to make the US less safe. He also spoke critically of Russian interference in the 2016 US elections and the way President Trump has handled the crisis. He does not consider Turkey a US ally and condemned the Turkish military offensive against US-aligned Kurdish forces in northeastern Syria.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.